^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Ovarian Cancer
    Drug:bemcentinib (BGB324) (AXL inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASCO 2020
    Title:

    Effect of inhibition of receptor tyrosine kinase AXL by a selective small molecular inhibitor R428 (BGB321) on DNA damage repair response in ovarian cancer cells.

    Published date:
    05/28/2020
    Excerpt:
    AXL inhibitor R428 sensitized both BRCA mutated and non-BRCA-mutated OC cells to a potent and highly selective ATR inhibitor.
    DOI:
    10.1200/JCO.2020.38.15_suppl.e15640